We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) closed at $248.43 in the latest trading session, marking a +2.04% move from the prior day. This change outpaced the S&P 500's 0.43% loss on the day. Meanwhile, the Dow experienced a drop of 1.05%, and the technology-dominated Nasdaq saw a decrease of 0.92%.
The world's biggest maker of health care products's stock has climbed by 7.12% in the past month, exceeding the Medical sector's loss of 1.34% and the S&P 500's loss of 0.5%.
The investment community will be closely monitoring the performance of Johnson & Johnson in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $2.68, reflecting a 3.25% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $23.43 billion, reflecting a 7.04% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $11.54 per share and a revenue of $100.29 billion, demonstrating changes of +6.95% and +6.47%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for Johnson & Johnson. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, Johnson & Johnson holds a Zacks Rank of #3 (Hold).
In terms of valuation, Johnson & Johnson is currently trading at a Forward P/E ratio of 21.1. For comparison, its industry has an average Forward P/E of 15.51, which means Johnson & Johnson is trading at a premium to the group.
Meanwhile, JNJ's PEG ratio is currently 2.36. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. JNJ's industry had an average PEG ratio of 2.26 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 168, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
Johnson & Johnson (JNJ - Free Report) closed at $248.43 in the latest trading session, marking a +2.04% move from the prior day. This change outpaced the S&P 500's 0.43% loss on the day. Meanwhile, the Dow experienced a drop of 1.05%, and the technology-dominated Nasdaq saw a decrease of 0.92%.
The world's biggest maker of health care products's stock has climbed by 7.12% in the past month, exceeding the Medical sector's loss of 1.34% and the S&P 500's loss of 0.5%.
The investment community will be closely monitoring the performance of Johnson & Johnson in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $2.68, reflecting a 3.25% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $23.43 billion, reflecting a 7.04% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $11.54 per share and a revenue of $100.29 billion, demonstrating changes of +6.95% and +6.47%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for Johnson & Johnson. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, Johnson & Johnson holds a Zacks Rank of #3 (Hold).
In terms of valuation, Johnson & Johnson is currently trading at a Forward P/E ratio of 21.1. For comparison, its industry has an average Forward P/E of 15.51, which means Johnson & Johnson is trading at a premium to the group.
Meanwhile, JNJ's PEG ratio is currently 2.36. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. JNJ's industry had an average PEG ratio of 2.26 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 168, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.